Holen Sie sich die Stockscreener-App
42.07
3.57%
1.45
Handel nachbörslich:
42.10
0.03
+0.07%
Schlusskurs vom Vortag:
$40.62
Offen:
$41.66
24-Stunden-Volumen:
2.83M
Relative Volume:
1.36
Marktkapitalisierung:
$5.21B
Einnahmen:
$692.26M
Nettoeinkommen (Verlust:
$-512.41M
KGV:
-9.9222
EPS:
-4.24
Netto-Cashflow:
$-274.36M
1W Leistung:
+10.71%
1M Leistung:
-10.20%
6M Leistung:
+18.44%
1J Leistung:
+55.24%
1-Tages-Spanne:
$39.70
$42.52
1-Wochen-Bereich:
$37.73
$42.52
52-Wochen-Spanne:
$20.14
$52.92
Guardant Health Inc Stock (GH) Company Profile
Firmenname
Guardant Health Inc
Sektor
Branche
Telefon
855-698-8887
Adresse
3100 HANOVER STREET, PALO ALTO
Vergleichen Sie GH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
42.07 | 4.85B | 692.26M | -512.41M | -274.36M | -4.24 |
|
TMO
Thermo Fisher Scientific Inc
|
396.45 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.27 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
514.80 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.07 | 31.59B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
139.06 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-01-23 | Eingeleitet | Barclays | Overweight |
| 2024-06-28 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-24 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-09-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-05-05 | Eingeleitet | UBS | Buy |
| 2023-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-11-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-04-28 | Fortgesetzt | BTIG Research | Buy |
| 2022-02-24 | Bestätigt | Canaccord Genuity | Buy |
| 2022-02-24 | Bestätigt | Citigroup | Buy |
| 2022-02-24 | Bestätigt | Cowen | Outperform |
| 2022-02-24 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-24 | Bestätigt | SVB Leerink | Outperform |
| 2022-02-24 | Bestätigt | Stifel | Buy |
| 2022-02-24 | Bestätigt | Wells Fargo | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-05-25 | Eingeleitet | Wells Fargo | Overweight |
| 2021-01-11 | Eingeleitet | Stifel | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-06-12 | Eingeleitet | BTIG Research | Buy |
| 2020-02-21 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-08-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-04-16 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Bestätigt | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-10-29 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-29 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Guardant Health Inc Aktie (GH) Neueste Nachrichten
Raymond James reaffirms Guardant Health stock rating after NCCN update - Investing.com Australia
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening - BioSpace
Guardant Health (GH) Gains NCCN Approval for Colorectal Cancer Test | GH Stock News - GuruFocus
Guardant Health Announced the results of the Serena-6 Phase III Trial - marketscreener.com
National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening | GH Stock News - GuruFocus
SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer - BioSpace
Liquid Biopsy Market for Cancer Detection, cfDNA & CTC Analysis | - openPR.com
Guardant Health (GH) Reveals Key Insights on Colon Cancer Recurrence | GH Stock News - GuruFocus
Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients - Insider Monkey
In Largest Molecular Residual Disease (MRD) Study in Colon Cance - GuruFocus
In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions - Yahoo Finance
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers - MSN
Guardant Health Inc (GH) Stock Price Up 5.11% on May 30 - GuruFocus
Upcoming Chicago Meeting for Guardant Health (GH) Investors | GH Stock News - GuruFocus
How Delfi Therapeutics plans to make liquid biopsies more accessible - The Business Journals
Guardant Health Inc (GH) Trading Down 3.27% on May 28 - GuruFocus
Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Nuveen Asset Management LLC - Defense World
Guardant Health enhances cancer blood test capabilities By Investing.com - Investing.com South Africa
Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way - Yahoo Finance
Guardant Health enhances cancer blood test capabilities - Investing.com Australia
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test | GH Stock News - GuruFocus
Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test - Eagle-Tribune
Ameriprise Financial Inc. Purchases 76,124 Shares of Guardant Health, Inc. (NASDAQ:GH) - Defense World
New Tests Promise to Reveal the Secrets in Your Blood - WSJ
Investor Attention Turns to Biotech as Traditional Cancer Research Models Strain - Baystreet.ca
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting - BioSpace
(GH) Technical Data - news.stocktradersdaily.com
Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting | GH Stock News - GuruFocus
Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know - Yahoo Finance
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio - Insider Monkey
Guardant Health Launches Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - BioSpace
Guardant Health, Inc. Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors - marketscreener.com
Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors | GH Stock News - GuruFocus
Guardant Health expands oncology testing with IHC suite - Investing.com
Guardant Health unveils new cancer risk test By Investing.com - Investing.com South Africa
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer - BioSpace
Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer | GH Stock News - GuruFocus
Guardant Health unveils new cancer risk test - Investing.com
Guardant Health: A Promising Player in the Liquid Biopsy Market - The Globe and Mail
Guardant Health: A Promising Player In The Liquid Biopsy Market - Barchart.com
New Horizons in Cancer Genetic Profiling Market Exploring - openPR.com
Finanzdaten der Guardant Health Inc-Aktie (GH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Guardant Health Inc-Aktie (GH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Tariq Musa | Director |
May 15 '25 |
Option Exercise |
0.00 |
250 |
0 |
3,595 |
| POTTER MYRTLE S | Director |
May 15 '25 |
Option Exercise |
0.00 |
68 |
0 |
14,063 |
| EAGLE CRAIG | Chief Medical Officer |
May 15 '25 |
Option Exercise |
0.00 |
3,718 |
0 |
36,318 |
| Chudova Darya | Chief Technology Officer |
May 15 '25 |
Option Exercise |
0.00 |
8,705 |
0 |
83,210 |
0.62%
1.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):